Lupin: Unit Nanomi Plans To Buy Up To 43.38% Of Multicare Pharmaceuticals Philippines For as Much as USD 39.6 Million, With Goal Of Taking Full Ownership By May 2026

 01 Apr 2026 07:02 PM

Lupin: Unit Nanomi Plans To Buy Up To 43.38% Of Multicare Pharmaceuticals Philippines For as Much as USD 39.6 Million, With Goal Of Taking Full Ownership By May 2026

Lupin: Co. Receives Tentative Approval from U.S. FDA for Sugammadex Injection

 01 Apr 2026 08:33 AM

Lupin: Co. Receives Tentative Approval from U.S. FDA for Sugammadex Injection

Lupin: co Gets Tentative U.S. FDA Approval For Sugammadex Injection

 31 Mar 2026 01:16 PM

Lupin: co Gets Tentative U.S. FDA Approval For Sugammadex Injection

Lupin: Subsidiary Multicare Pharmaceuticals Philippines Buys Back 2,813,811 Shares, Boosting Nanomi’s Stake In MPPI From 51% To 56.28%.

 30 Mar 2026 09:42 AM

Lupin: Subsidiary Multicare Pharmaceuticals Philippines Buys Back 2,813,811 Shares, Boosting Nanomi’s Stake In MPPI From 51% To 56.28%.

Lupin: Gets Tentative U.S. FDA Approval For Pitolisant Tablets 4.45mg And 17.8mg

 25 Mar 2026 06:04 PM

Lupin: Gets Tentative U.S. FDA Approval For Pitolisant Tablets 4.45mg And 17.8mg

Lupin: U.S. FDA Gives Tentative Approval To Pitolisant Tablets

 25 Mar 2026 09:20 AM

Lupin: U.S. FDA Gives Tentative Approval To Pitolisant Tablets

Lupin: Company Announces Expansion of Manufacturing Facility in Dabhasa, India, Boosting Development and Manufacturing Strengths.

 19 Mar 2026 08:24 AM

Lupin: Company Announces Expansion of Manufacturing Facility in Dabhasa, India, Boosting Development and Manufacturing Strengths.

Lupin: Enters Licensing Deal With Zydus Lifesciences To Co-Brand Semaglutide Injection In India; Zydus Will Market As Semaglyntm, Mashematm, Altermetm, While Lupin Will Use The Names Semanext® And Livarise®.

 17 Mar 2026 12:02 PM

Lupin: Enters Licensing Deal With Zydus Lifesciences To Co-Brand Semaglutide Injection In India; Zydus Will Market As Semaglyntm, Mashematm, Altermetm, While Lupin Will Use The Names Semanext® And Livarise®.

Lupin: Company Reports Cargo Movement Affected Due To Container Delays At Ports From Europe And The Middle East.-Cnbc TV18

 09 Mar 2026 12:33 PM

Lupin: Company Reports Cargo Movement Affected Due To Container Delays At Ports From Europe And The Middle East.-Cnbc TV18

Lupin: Higher Oil Prices May Cause Increase in Solvent Costs

 09 Mar 2026 12:35 PM

Lupin: Higher Oil Prices May Cause Increase in Solvent Costs

Lupin: Morgan Stanley maintains Equal-Weight on Lupin Limited with Target Price Rs 2,386, noting the USFDA Form 483 with only two observations indicates manageable compliance risk, while FY26 is expected to deliver a second consecutive year of strong earnings growth.

 09 Mar 2026 09:12 AM

Lupin: Morgan Stanley maintains Equal-Weight on Lupin Limited with Target Price Rs 2,386, noting the USFDA Form 483 with only two observations indicates manageable compliance risk, while FY26 is expected to deliver a second consecutive year of strong earnings growth.

Lupin: USFDA Inspection At Lupin's Ankleshwar Plant Ends With Two Observations.

 09 Mar 2026 08:45 AM

Lupin: USFDA Inspection At Lupin's Ankleshwar Plant Ends With Two Observations.

Lupin: Goldman Sachs on Lupin Neutral, Target Price Rs 2275

 05 Mar 2026 09:05 AM

Lupin: Goldman Sachs on Lupin Neutral, Target Price Rs 2275

Lupin: Maharashtra GST Department Finishes Inspection With No Negative Findings; No Effect On Co's Financials

 02 Mar 2026 09:11 PM

Lupin: Maharashtra GST Department Finishes Inspection With No Negative Findings; No Effect On Co's Financials

Lupin: Nanomi B.V. Delays Purchase of Visufarma B.V.; Deal Now Anticipated to Finalize in April 2026, Awaiting Required Approvals

 27 Feb 2026 07:45 PM

Lupin: Nanomi B.V. Delays Purchase of Visufarma B.V.; Deal Now Anticipated to Finalize in April 2026, Awaiting Required Approvals

Lupin: Gets Satisfactory Establishment Inspection Report From US FDA For Goa Facility, With Voluntary Action Indicated.

 27 Feb 2026 01:01 PM

Lupin: Gets Satisfactory Establishment Inspection Report From US FDA For Goa Facility, With Voluntary Action Indicated.

Lupin: Company Gets FDA Approval For Brivaracetam Oral Solution, Estimated U.S. Sales Of $135 Million

 24 Feb 2026 07:21 PM

Lupin: Company Gets FDA Approval For Brivaracetam Oral Solution, Estimated U.S. Sales Of $135 Million

Lupin: Gets European Commission Approval For Biosimilar Ranibizumab; Sandoz To Market Product In EU, Excluding Germany; Confirms Company's Dedication To Affordable Biologic Treatments

 23 Feb 2026 03:28 PM

Lupin: Gets European Commission Approval For Biosimilar Ranibizumab; Sandoz To Market Product In EU, Excluding Germany; Confirms Company's Dedication To Affordable Biologic Treatments

Lupin: USFDA Inspects Lupin's Largest Goa Facility, Raises Concerns About Quality Control Issues - CNBC TV18

 19 Feb 2026 10:59 AM

Lupin: USFDA Inspects Lupin's Largest Goa Facility, Raises Concerns About Quality Control Issues - CNBC TV18

Lupin: Company Partners With Spektus To Distribute New Antidepressant Deslaflex In Canada

 16 Feb 2026 05:41 PM

Lupin: Company Partners With Spektus To Distribute New Antidepressant Deslaflex In Canada